Literature DB >> 15629222

Evolution and dissemination of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae: epidemiology and molecular report from the SENTRY Antimicrobial Surveillance Program (1997-2003).

Joseph R DiPersio1, Lalitagauri M Deshpande, Douglas J Biedenbach, Mark A Toleman, Timothy R Walsh, Ronald N Jones.   

Abstract

During 2001, occurrences of extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae isolates were detected in a single medical center (Hospital A) from the SENTRY Antimicrobial Surveillance Program that became endemic in long-term acute care areas and in the intensive care unit in 2002-2003. Between 2001 and 2003, 123 patients were infected or colonized with ESBL-positive K. pneumoniae. Resistance profiles were determined by reference broth microdilution methods, and automated ribotyping and pulsed-field gel electrophoresis (PFGE) were performed. The ESBL-positive K. pneumoniae isolates were resistant to aztreonam, ceftazidime, aminoglycosides, and trimethoprim/sulfamethoxazole and susceptible to ciprofloxacin and tetracycline. In 1997, 1998, and 2000, 9 ESBL-producing K. pneumoniae strains from 2 New York City hospitals shared the same antibiograms and ribotype (204.2) as the strains from Hospital A. PFGE patterns divided Hospital A isolates into 2 subtypes (A and A1) and 3 New York City strains were similar to the Hospital A isolates (A2, A3, and A4). Isoelectric focusing studies of 1 New York City isolate (A4) revealed pIs at 5.4, 7.7, and 8.2. PCR and sequencing results from 1 strain of each Hospital A and 1 New York PFGE pattern determined that TEM-1 and SHV-5 (ESBL) were present in all strains. In addition, 2 New York isolates from 1998 (A3 and A4) also had an OXA-2 enzyme. ESBL-producing K. pneumoniae isolates with ribotype 204.2 from SENTRY Program sites have been recognized in New York only since 1997 and in Hospital A beginning in 2001. The similarities of the antibiogram and epidemiological patterns suggest that these isolates have persisted over time and may have evolved into different but genetically related endemic ESBL-positive K. pneumoniae clones that have the ability to cause sustained epidemic outbreaks in US medical centers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15629222     DOI: 10.1016/j.diagmicrobio.2004.08.001

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  6 in total

1.  Inhibition of gene expression and growth by antisense peptide nucleic acids in a multiresistant beta-lactamase-producing Klebsiella pneumoniae strain.

Authors:  Prathiba Kurupati; Kevin Shyong Wei Tan; Gamini Kumarasinghe; Chit Laa Poh
Journal:  Antimicrob Agents Chemother       Date:  2006-12-11       Impact factor: 5.191

2.  Prevalence and significance of a negative extended-spectrum beta-lactamase (ESBL) confirmation test result after a positive ESBL screening test result for isolates of Escherichia coli and Klebsiella pneumoniae: results from the SENTRY Asia-Pacific Surveillance Program.

Authors:  Jan M Bell; Mohsen Chitsaz; John D Turnidge; Mary Barton; Luke J Walters; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2007-03-07       Impact factor: 5.948

3.  A step towards the discrimination of beta-lactamase-producing clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa by MALDI-TOF mass spectrometry.

Authors:  Reiner Schaumann; Nicolas Knoop; Gelimer H Genzel; Kevin Losensky; Christiane Rosenkranz; Catalina S Stîngu; Wolfgang Schellenberger; Arne C Rodloff; Klaus Eschrich
Journal:  Med Sci Monit       Date:  2012-09

4.  Instant Typing Is Essential to Detect Transmission of Extended-Spectrum Beta-Lactamase-Producing Klebsiella Species.

Authors:  Anne F Voor in 't Holt; Juliëtte A Severin; Wil H F Goessens; René Te Witt; Margreet C Vos
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

5.  Organic Extract of Justicia pectoralis Jacq. Leaf Inhibits Interferon-γ Secretion and Has Bacteriostatic Activity against Acinetobacter baumannii and Klebsiella pneumoniae.

Authors:  Tiago Rafael de Sousa Nunes; Marina Ferraz Cordeiro; Fernanda Gomes Beserra; Matheus Landim de Souza; Wliana Alves Viturino da Silva; Magda Rhayanny Assunção Ferreira; Luiz Alberto Lira Soares; Sérgio Dias Costa-Junior; Isabella Macário Ferro Cavalcanti; Maira Galdino da Rocha Pitta; Ivan da Rocha Pitta; Moacyr Jesus Barreto de Melo Rêgo
Journal:  Evid Based Complement Alternat Med       Date:  2018-08-23       Impact factor: 2.629

6.  Study of a Natural Mutant SHV-Type β -Lactamase, SHV-104, from Klebsiella pneumoniae.

Authors:  Nahed Ben Achour; Omrane Belhadj; Moreno Galleni; Mohamed Ben Moussa; Paola Sandra Mercuri
Journal:  Int J Microbiol       Date:  2014-05-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.